AR095764A1 - Derivados de ácido biaril-propiónico y su uso como productos farmacéuticos - Google Patents

Derivados de ácido biaril-propiónico y su uso como productos farmacéuticos

Info

Publication number
AR095764A1
AR095764A1 ARP140101374A ARP140101374A AR095764A1 AR 095764 A1 AR095764 A1 AR 095764A1 AR P140101374 A ARP140101374 A AR P140101374A AR P140101374 A ARP140101374 A AR P140101374A AR 095764 A1 AR095764 A1 AR 095764A1
Authority
AR
Argentina
Prior art keywords
alkyl
ocf3
cycloalkyl
ch2oh
diseases
Prior art date
Application number
ARP140101374A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR095764A1 publication Critical patent/AR095764A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ellos son inhibidores de la proteasa catepsina A, y son útiles para el tratamiento de enfermedades tales como ateroesclerosis, insuficiencia cardíaca, enfermedades renales, enfermedades hepáticas o enfermedades inflamatorias, por ejemplo, se refiere además a procedimientos para la preparación de los compuestos de la fórmula (1), a su uso y a las composiciones farmacéuticas que los contienen. Reivindicación 1: Un compuesto de la fórmula (1), en cualquiera de sus formas estereoisómeras o una mezcla de formas estereoisómeras en cualquier proporción, o una de sus sales fisiológicamente aceptables, o un solvato fisiológicamente aceptable de cualquiera de ellas, en donde los significados son: X es S ó O; D es N o -C(R3)=; R es H, alquilo C₁₋₆, cicloalquilo C₃₋₈; R¹ es H, alquilo C₁₋₆, cicloalquilo C₃₋₈, alquilen C₁₋₆-cicloalquilo C₃₋₈; en donde alquilo está opcionalmente sustituido con uno o más átomos de F; R³ es H, metilo o etilo; R² es hidrógeno o alquilo C₁₋₆; E¹ es N o -C(R⁴)=; E² es N o -C(R⁵)=; E³ es N o -C(R⁶)=; E⁴ es N o -C(R⁷)=; en donde ninguno o uno de E¹, E², E³ o E⁴ es N; R⁴ es H o O-alquilo C₁₋₆; R⁵ es H, F, Cl, CF₃, alquilo C₁₋₆, cicloalquilo C₁₋₆; R⁶ es H o -O-CH₂-fenilo; R⁷ es H; G¹ es N o -C(R⁸)=; G² es N o -C(R⁹)=; G³ es N o -C(R¹⁰)=; G⁴ es N o -C(R¹¹)=; en donde ninguno o uno de G¹, G², G³ o G⁴ es N; o G³ y G⁴ son -C(R¹⁰)= y -C(R¹¹)=, en donde R¹⁰ y R¹¹ forman un carbociclo o heterociclo saturado de 4 a 7 miembros con uno o dos átomos de oxígeno; que está opcionalmente monosustituido o disustituido con alquilo C₁₋₃; R⁸ es H, F, Cl, alquilo C₁₋₆, O-alquilo C₁₋₆, CF₃ o OCF₃; R⁹ es H, F, Cl, OH, O-alquilo C₁₋₆, CH₂OH, CO-NH₂, alquilo C₁₋₆, O-alquilo C₁₋₆, CF₃ o OCF₃; R¹⁰ es H, F, Cl, OH, alquilo C₁₋₆, CH₂OH, CO-O-alquilo C₁₋₆, SO₂-alquilo C₁₋₆, CN, O-alquilo C₁₋₆, CF₃, CH₂-CN, (C(CH₃)₂)-CN, alquil C₁₋₆-OH, -O-alquil C₁₋₆-OH, -O-CH₂-CO-alquilo C₁₋₆ o OCF₃; R¹¹ es H, F, Cl, OH, O-alquilo C₁₋₆, CH₂OH, CO-C₁₋₆-metilo, CO-N(R²⁰R²¹), CO-O-alquilo C₁₋₆, CN, alquilo C₁₋₆, O-alquilo C₁₋₆ o OCF₃; en donde R²⁰ y R²¹ son independientemente uno de otro, H o alquilo C₁₋₃ o forman junto con el nitrógeno al que están unidos un anillo saturado de 5 ó 6 miembros.
ARP140101374A 2013-03-28 2014-03-26 Derivados de ácido biaril-propiónico y su uso como productos farmacéuticos AR095764A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13305401 2013-03-28

Publications (1)

Publication Number Publication Date
AR095764A1 true AR095764A1 (es) 2015-11-11

Family

ID=48050627

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101374A AR095764A1 (es) 2013-03-28 2014-03-26 Derivados de ácido biaril-propiónico y su uso como productos farmacéuticos

Country Status (14)

Country Link
US (1) US9150526B2 (es)
EP (1) EP2978754B1 (es)
JP (1) JP6359634B2 (es)
KR (1) KR20150136507A (es)
CN (1) CN105051038B (es)
AR (1) AR095764A1 (es)
AU (1) AU2014243069B2 (es)
CA (1) CA2907903A1 (es)
IL (1) IL240422B (es)
MX (1) MX2015013800A (es)
SG (1) SG11201506190QA (es)
TW (1) TW201514158A (es)
UY (1) UY35515A (es)
WO (1) WO2014154726A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051518A (en) * 1987-05-29 1991-09-24 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
US20040072802A1 (en) 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
MXPA05006200A (es) 2002-12-23 2005-08-19 Aventis Pharma Gmbh Derivados de pirazol como inhibidores del factor xa.
JP2005145839A (ja) 2003-11-12 2005-06-09 Japan Science & Technology Agency 新規なカテプシンａ阻害剤
WO2006076202A1 (en) 2005-01-10 2006-07-20 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
WO2009080226A2 (en) 2007-12-26 2009-07-02 Sanofis-Aventis Heterocyclic pyrazole-carboxamides as p2y12 antagonists
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
TWI532725B (zh) * 2010-01-26 2016-05-11 賽諾菲阿凡提斯公司 經氧取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
AR085013A1 (es) 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
TWI523844B (zh) * 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
CA2841905A1 (en) * 2011-07-26 2013-01-31 Sanofi 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
RU2617843C2 (ru) * 2011-07-26 2017-04-28 Санофи Замещенные производные 3-тиазолоаминопропионовой кислоты и их применение в качестве фармацевтических препаратов
US20130123276A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US20130123325A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases

Also Published As

Publication number Publication date
EP2978754A1 (en) 2016-02-03
KR20150136507A (ko) 2015-12-07
AU2014243069A1 (en) 2015-09-24
IL240422B (en) 2018-12-31
AU2014243069B2 (en) 2017-12-21
TW201514158A (zh) 2015-04-16
US9150526B2 (en) 2015-10-06
IL240422A0 (en) 2015-09-24
MX2015013800A (es) 2016-06-02
JP6359634B2 (ja) 2018-07-18
JP2016515558A (ja) 2016-05-30
CN105051038B (zh) 2018-08-03
EP2978754B1 (en) 2017-05-10
UY35515A (es) 2014-10-31
CA2907903A1 (en) 2014-10-02
WO2014154726A1 (en) 2014-10-02
SG11201506190QA (en) 2015-09-29
US20140296296A1 (en) 2014-10-02
CN105051038A (zh) 2015-11-11

Similar Documents

Publication Publication Date Title
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR106472A1 (es) Inhibidores de acc y usos de los mismos
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
AR105875A1 (es) Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio
AR106100A1 (es) Compuestos bicíclicos como inhibidores duales atx / ca
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100714A1 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
AR089944A1 (es) Derivados de tetrahidro-quinazolinona
AR082109A1 (es) Derivados de bipiridilo
AR094790A1 (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
AR095279A1 (es) N-(4-(azaindazol-6-il)-fenil)-sulfonamidas y su uso como productos farmacéuticos
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR105522A1 (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor
AR104880A1 (es) MODULADORES DE ROR GAMMA (RORg)
AR094735A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4
AR106604A1 (es) Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico
AR079967A1 (es) Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos
PE20200445A1 (es) Inhibidores pirazolicos de magl
AR097755A1 (es) Derivados sustituidos de fenilalanina como moduladores del factor xia
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения

Legal Events

Date Code Title Description
FB Suspension of granting procedure